Joseph R. Lacy, M.D., is a neurologist with the Palo Alto Medical Foundation and practices in Palo Alto and San Carlos. He is board certified in neurology & electrodiagnostic medicine.
Dr. Lacy received his medical education at the University of Vermont and neurology residency at the University of Pennsylvania. His fellowship training was completed at the National Institute of Neurological Communicative Disorders and Stroke, National Institutes of Health.
Sutter Health Research Enterprise
795 El Camino Real
Palo Alto, CA, 94301-2302
Related Clinical Trials
An open-label, single-arm study to evaluate the effectiveness and safety of ocrelizumab in patients with early stage relapsing remitting multiple sclerosis.
Investigator: Joseph R. Lacy M.D.
Treatment of refractory chronic demyelinating polyneuropathy with lymphoid irradiation.
Results of this preliminary study: radiotherapy deserves further study in the treatment of chronic progressive demyelinating polyneuropathy.
Intracardiac papillary fibroelastoma: an occult cause of embolic neurologic deficit.
The intracardiac papillary fibroelastoma as an uncommon source of occult cerebral emboli is discussed.
Tramadol/acetaminophen combination tablets and codeine/acetaminophen combination capsules for the management of chronic pain: a comparative trial.
Results: Tramadol/APAP tablets are as effective as codeine/ APAP capsules in tx of chronic nonmalignant low back and OA pain and are better tolerated.
Interferon beta-1a in children with multiple sclerosis is well tolerated.
Preliminary data indicate that weekly intramuscular injections of interferon-beta-1a are well tolerated in children with multiple sclerosis.
Identification of short-term pharmacodynamic effects of interferon-beta-1a in multiple sclerosis subjects with broad- based phenotypic profiling.
A strong pharmacodynamic effect of interferon-beta-1a in multiple sclerosis was observed 1.5 (short-term) vs. 6 days post weekly injection.